Jazz Pharmaceuticals Announces Phase 3 LAGOON Study Of Zepzelca In Participants With Relapsed Metastatic Small Cell Lung Cancer Failed To Meet Primary Endpoint Of Overall Survival

뉴스 본문을 불러오고 있어요.

Jazz Pharmaceuticals Announces Phase 3 LAGOON Study Of Zepzelca In Participants With Relapsed Metastatic Small Cell Lung Cancer Failed To Meet Primary Endpoint Of Overall Survival | 웨이프 WAPE

Jazz Pharmaceuticals Announces Phase 3 LAGOON Study Of Zepzelca In Participants With Relapsed Metastatic Small Cell Lung Cancer Failed To Meet Primary Endpoint Of Overall Survival

기사 요약

관련 종목

댓글 —